The latest on building what’s next.

 Celltrion USA Appoints Thomas Nusbickel as Chief Commercial Officer Seasoned commercial operations executive brings three decades of global biopharmaceutical industry experience to Celltrion USA’s leadership team February 06, 2023, CHICAGO, IL –Celltrion USA, a global leader in expanding access to innovative biologics, today announced the appointment of Thomas Nusbickel as Chief Commercial Officer.  Mr. Nusbickel will oversee the company’s commercial operations […]

Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous formulation of CT-P13 to U.S. Food and Drug Administration  CT-P13 SC is a novel subcutaneous formulation of infliximabThe Biologics License Application (BLA) submission is based on phase III pivotal data that evaluated the efficacy and safety of CT-P13 SC as maintenance therapy in […]

Celltrion USA Receives U.S. FDA Approval for its Oncology Biosimilar Vegzelma® (bevacizumab-adcd) for the Treatment of Six Types of CancerVegzelma® is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDAVegzelma® offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment optionThe approval is based on totality of evidence with no clinically […]